Bjarne Bogen and collaborators

Nykode Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of modular DNA vaccines and novel immunotherapies. The company's core technology, the Vaccibody platform, was originally developed by Professor Bjarne Bogen and his collaborators at the University of Oslo to target antigens directly to antigen-presenting cells. This platform enables the creation of vaccines that can trigger a rapid, strong, and specific immune response by utilizing a unique three-module design. Nykode's lead program, VB10.16, is a therapeutic vaccine targeting HPV16-positive cancers, which has demonstrated clinical efficacy in Phase 2 trials for cervical cancer. The company has secured major strategic partnerships with Genentech and Regeneron to advance its pipeline of personalized cancer vaccines and combination therapies.